Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Sep;6(9):535-43.
doi: 10.1038/nrclinonc.2009.112. Epub 2009 Aug 4.

Imatinib and beyond--exploring the full potential of _targeted therapy for CML

Alfonso Quintás-Cardama  1 , Hagop Kantarjian, Jorge Cortes
Affiliations
Review

Imatinib and beyond--exploring the full potential of _targeted therapy for CML

Alfonso Quintás-Cardama et al. Nat Rev Clin Oncol. 2009 Sep.

Abstract

A subset of patients with chronic myeloid leukemia (CML) who receive imatinib therapy will require alternative therapy at some point owing to safety reasons or lack of efficacy. Achieving an early response with imatinib is protective against treatment failure; second-generation tyrosine kinase inhibitors (TKIs; for example, nilotinib, dasatinib, bosutinib), however, have proven to be efficacious at restoring cytogenetic responses in patients who require subsequent therapy. Response duration, however, is yet to be established and a considerable proportion of patients fail to achieve a clinically meaningful response. A third generation of TKIs is currently undergoing clinical testing for use in patients who fail imatinib and a second-generation TKI. Most of these agents are multikinase inhibitors with activity against a wide variety of BCR-ABL1 mutations, including the highly resistant T315I. The use of second-generation TKIs in the frontline setting seems to provide higher rates of early response compared with imatinib. If these results are confirmed in randomized studies, nilotinib and dasatinib could replace imatinib as standard frontline therapy in CML. Despite the activity of all of the above mentioned agents, curing CML will ultimately depend on the development of agents capable of vanquishing BCR-ABL1-positive CML stem cells. Efforts aimed at achieving this goal are ongoing.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nat Rev Drug Discov. 2007 Oct;6(10):834-48 - PubMed
    1. Leukemia. 2008 Jun;22(6):1200-6 - PubMed
    1. Blood. 2004 Apr 15;103(8):2873-8 - PubMed
    1. J Clin Oncol. 2008 Jul 10;26(20):3358-63 - PubMed
    1. Leukemia. 2005 Jun;19(6):1034-41 - PubMed

MeSH terms

LinkOut - more resources

  NODES
twitter 2